When was Relmada founded?

Relmada was founded in 2007 and raised its 1st funding round 6 years after it was founded.

Where is Relmada located?

Relmada is headquartered in Blue Bell, United States.

How many employees does Relmada have?

As of Sep 30, 2026, the latest employee count at Relmada is 32.

Is Relmada a funded company?

Relmada is a funded company, having raised a total of $13M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 06, 2013.

When was the latest funding round of Relmada?

Relmada's latest funding was a $***** Post IPO round on Oct 08, 2019, with participation from 0 investor.

What is the annual revenue of Relmada?

Annual revenue of Relmada is less than $1M as on Aug 31, 2013

Where does Relmada rank among its competitors?

Relmada ranks 5th amongst 14 active competitors, of which 2 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was OncoSTING, which secured $2.24M in Dec, 2025.

Who are the top competitors of Relmada?

Relmada's top competitors include UroGen Pharma, Lipella and Protara Therapeutics. Among them, OncoSTING secured the most recent funding round in December, 2025.

Relmada - 2026 Company Profile, Team, Funding, Competitors & Financials

Relmada is a public company based in Blue Bell (United States), founded in 2007 by Najib Babul. It operates as a Developing innovative therapies for debilitating disorders, improving human health. Relmada has raised $13M in funding from BioAdvance and Ben Franklin Technology Partners. The company has 14 active competitors, including 2 funded and 5 that have exited. Its top competitors include companies like UroGen Pharma, Lipella and Protara Therapeutics.

Company Details

Developing innovative therapies for debilitating disorders, improving human health. This biopharmaceutical company is dedicated to the research and development of transformative medicines. The company focuses on progressing its product pipeline and exploring product opportunities. With a team bringing decades of drug development experience and extensive expertise, it aims to address well-defined and underserved markets. The company maintains active surveillance to consider programs that have the potential to be high-value assets. The goal is providing curative treatments to patients, unlocking life-changing therapies. The company's scientific advisory board spans world-class academic and medical institutions.

Website: www.relmada.com/
Social

Key Metrics

Founded Year

2007

Location

Blue Bell, United States

Stage

Public

Total Funding

$13M in 9 rounds

Latest Funding Round

Post IPO, Oct 08, 2019, $*****

Investors

BioAdvance & 2 more

Ranked

5^th among 14 active competitors

Annual Revenue

$0 - $1M as on Aug 31, 2013

Employee Count

32 as on Sep 30, 2026

Similar Companies

UroGen Pharma & 16 more

Exit Details

Public

View Relmada's full profile

Relmada is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
RELMADA THERAPEUTICS, INC. CIN: 1553643 , United States, Active	Feb 08, 2007	$0 - $1M (As on Aug 31, 2013)	14 (As on Jun 30, 2022)	-
Relmada Therapeutics, Inc CIN: 45-5401931 , United States, Active	Feb 08, 2007	-	10 (As on Dec 31, 2021)	-

Relmada got listed on May 20, 2014.

Click here to take a look at Relmada's IPO in detail

Relmada has raised a total funding of $13M over 9 rounds. Its first funding round was on Jun 06, 2013. Relmada has 3 institutional investors.

Here is the list of recent funding rounds of Relmada:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 08, 2019	3396196	Post IPO	7751689	9100339	7049597	8801466
Jun 2019	8484603	Post IPO	1034043	7452691	5488934	5023745
May 16, 2019	6965879	Post IPO	3618369	5461021	7097578	7402455

Access funding benchmarks and valuations. Sign up today!

View details of Relmada's funding rounds and investors

The founders of Relmada is Najib Babul.

Here are the details of Relmada's key team members:

Najib Babul: Former Founder of Relmada.
Sergio Traversa: CEO of Relmada.
Contact Info: 1 email address

View details of Relmada's Founder profiles and Board Members

Relmada's employee count trend

Relmada has 32 employees as of Sep 26. Here is Relmada's employee count trend over the years:

Uncover Relmada's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Relmada include UroGen Pharma, Lipella and Protara Therapeutics. Here is the list of Top 10 competitors of Relmada, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	UroGen Pharma 2004, Ra anana (Israel), Public	Developer of therapeutics to treat urothelial and specialty cancers	$7M	Sonostar Ventures, hortoncapital.com & 12 others	64/100
2nd	Lipella 2005, Pittsburgh (United States), Public	Developer of lipid-based therapies for common bladder syndromes	$3.37M	Military Health, HHS	57/100
3rd	Protara Therapeutics 2017, New York City (United States), Public	Developer of cell therapies to treat lymphatic malfunctions	-	TVM Capital Life Science, Boxer Capital & 8 others	52/100
4th	Prokarium 2012, London (United Kingdom), Series C	Developer of bacterial immunotherapy treatments for various types of cancer	$70M	Korea Investment Holdings, Riyadh Valley Company ... & 9 others	52/100
5th	Relmada 2007, Blue Bell (United States), Public	Developing innovative therapies for debilitating disorders, improving human health	$13M	BioAdvance, Ben Franklin Technology Partners ... & 1 others	52/100
6th	Asieris Pharmaceuticals 2010, Radnor (United States), Unfunded	Developer of drugs for the treatment of genitourinary tumors and other major diseases	-	-	50/100
7th	Rainer Theraputics 2010, San Leandro (United States), Deadpooled	Developer of antibody based therapeutics for bladder cancer	$156M	Sectoral, Sofinnova Investments & 7 others	35/100
8th	Tengion 2004, Audubon (United States), Deadpooled	Regenerative medicine company developing neo-organs & neo-tissues.	$143M	Quaker Partners, Brookside Capital & 14 others	35/100
9th	Tollys 2015, Lyon (France), Series A	Developer of drugs for treating cancer	$6.97M	Bpifrance	34/100
10th	OncoSTING 2018, Baltimore (United States), Funding Raised	Developer of immunotherapy for bladder cancer	-	HHS	32/100